Stallergenes : Investor Meeting: Webcast is Available

PARIS - Hello,

The investor meeting relating to the 2008 earnings and 2009
outlook has been webcasted. The presentation is available in English from the
following link:

www.thomson-webcast.net/uk/dispatching/?event_id=2ef87b3007af7a71a2e0f120f7f05e9c&portal_id=55a3fb63ef049550bc3b4d09baf7bf5e

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated
to desensitization therapies for the prevention and treatment of
allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic
asthma. A pioneer and leader in sublingual desensitization treatments,
Stallergenes devotes 21% (gross) of its sales to Research and Development and
is actively involved in the development of a new therapeutic class:
sublingual desensitization tablets.

In 2008, Stallergenes had sales of EUR 171 million and
provided desensitization treatments to more than 500,000 patients.

Euronext Paris (Compartment B)
SBF 120.
ISIN Code: FR0000065674
Reuters Code: GEN.PA
Bloomberg Code: GEN.FP

Additional financial information is available at
www.stallergenes.com

Source: Stallergenes

Lucile de FRAGUIER, PAVIE FINANCE, T : +33(0)1-42-15-04-39, mailto:contact at pavie-finance.com